[
  {
    "ts": "2026-01-13T10:24:00+00:00",
    "headline": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
    "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
    "url": "https://www.barrons.com/articles/abbvie-stock-trump-tariffs-deal-4f08ec87?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "1d0e3ef9-8bce-3c03-92ed-9f3f6b25fa5f",
      "content": {
        "id": "1d0e3ef9-8bce-3c03-92ed-9f3f6b25fa5f",
        "contentType": "STORY",
        "title": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
        "description": "",
        "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
        "pubDate": "2026-01-13T10:24:00Z",
        "displayTime": "2026-01-13T10:24:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/1d0e3ef9-8bce-3c03-92ed-9f3f6b25fa5f/abbvie-strikes-a-100-billion.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/0a2845aa6b4185d51e8f8c6cc2b1e7a8",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uprYtz96.huIUAIJcxlT7w--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/0a2845aa6b4185d51e8f8c6cc2b1e7a8.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LhuGYFvbZhLBqQD88UWabQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/0a2845aa6b4185d51e8f8c6cc2b1e7a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/abbvie-stock-trump-tariffs-deal-4f08ec87?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T12:48:28+00:00",
    "headline": "Tempus AI (TEM) Soars 15% on $1.1-Billion Deal",
    "summary": "We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]",
    "url": "https://finance.yahoo.com/news/tempus-ai-tem-soars-15-124828137.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "8cd6eab2-2b32-3342-b8c7-afc388628b1c",
      "content": {
        "id": "8cd6eab2-2b32-3342-b8c7-afc388628b1c",
        "contentType": "STORY",
        "title": "Tempus AI (TEM) Soars 15% on $1.1-Billion Deal",
        "description": "",
        "summary": "We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]",
        "pubDate": "2026-01-13T12:48:28Z",
        "displayTime": "2026-01-13T12:48:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4edc292b1dcbd797c07f522ebf66f3cd",
          "originalWidth": 768,
          "originalHeight": 512,
          "caption": "Tempus AI (TEM) Soars 15% on $1.1-Billion Deal",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wpXHllSshAhvRjKQLWZ8dQ--~B/aD01MTI7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4edc292b1dcbd797c07f522ebf66f3cd.cf.webp",
              "width": 768,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V0NnFlegXm2HaeSZe_vD3A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4edc292b1dcbd797c07f522ebf66f3cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tempus-ai-tem-soars-15-124828137.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tempus-ai-tem-soars-15-124828137.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "TEM"
            },
            {
              "symbol": "DSKYF"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "WHWK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T14:15:00+00:00",
    "headline": "Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery",
    "summary": "Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of human disease biology to date.",
    "url": "https://finance.yahoo.com/news/illumina-introduces-billion-cell-atlas-141500418.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "b51307e1-1bc0-33d1-8dc4-662456728aa9",
      "content": {
        "id": "b51307e1-1bc0-33d1-8dc4-662456728aa9",
        "contentType": "STORY",
        "title": "Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery",
        "description": "",
        "summary": "Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of human disease biology to date.",
        "pubDate": "2026-01-13T14:15:00Z",
        "displayTime": "2026-01-13T14:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/5303c01dbf70dd6a5a3a65f64bcf2446",
          "originalWidth": 400,
          "originalHeight": 225,
          "caption": "Illumina introduces Billion Cell Atlas",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rCcVV0ZeIzUFY.SzuayEdA--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/5303c01dbf70dd6a5a3a65f64bcf2446.cf.webp",
              "width": 400,
              "height": 225,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N5nx5mIqzTOKOGtiqvHoWw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/5303c01dbf70dd6a5a3a65f64bcf2446.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/illumina-introduces-billion-cell-atlas-141500418.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/illumina-introduces-billion-cell-atlas-141500418.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ILMN"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T12:54:00+00:00",
    "headline": "Inside Pfizer's Oncology Performance Ahead of Q4 Results",
    "summary": "PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.",
    "url": "https://finance.yahoo.com/news/inside-pfizers-oncology-performance-ahead-125400114.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "75248d53-dea8-362e-8707-5f73901ab206",
      "content": {
        "id": "75248d53-dea8-362e-8707-5f73901ab206",
        "contentType": "STORY",
        "title": "Inside Pfizer's Oncology Performance Ahead of Q4 Results",
        "description": "",
        "summary": "PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.",
        "pubDate": "2026-01-13T12:54:00Z",
        "displayTime": "2026-01-13T12:54:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WtA490SSyXq.BB5XEEYFSg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BdQSUWaJAMCKg7gp75c9jQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/inside-pfizers-oncology-performance-ahead-125400114.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/inside-pfizers-oncology-performance-ahead-125400114.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T15:48:54+00:00",
    "headline": "Merck KGaA Touts “Next Wave of Growth” at JPM Healthcare, Reaffirms 2025 Guidance, Eyes 2026 Upside",
    "summary": "Merck KGaA (ETR:MRK) Chief Executive Officer Belén Garijo used the company’s presentation at the 44th J.P. Morgan Healthcare Conference to outline what she described as a “next wave of growth,” anchored by three strategic growth pillars: Process Solutions in Life Science, rare diseases in Healthcare",
    "url": "https://www.marketbeat.com/instant-alerts/merck-kgaa-touts-next-wave-of-growth-at-jpm-healthcare-reaffirms-2025-guidance-eyes-2026-upside-2026-01-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "64c37b50-4eb3-32a5-a7b9-3e57d8c7a33d",
      "content": {
        "id": "64c37b50-4eb3-32a5-a7b9-3e57d8c7a33d",
        "contentType": "STORY",
        "title": "Merck KGaA Touts “Next Wave of Growth” at JPM Healthcare, Reaffirms 2025 Guidance, Eyes 2026 Upside",
        "description": "",
        "summary": "Merck KGaA (ETR:MRK) Chief Executive Officer Belén Garijo used the company’s presentation at the 44th J.P. Morgan Healthcare Conference to outline what she described as a “next wave of growth,” anchored by three strategic growth pillars: Process Solutions in Life Science, rare diseases in Healthcare",
        "pubDate": "2026-01-13T15:48:54Z",
        "displayTime": "2026-01-13T15:48:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/2714949d049301fe53cf9c4c80007f58",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Merck KGaA logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8Wud6PUbluU9ERg8hpQucA--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/2714949d049301fe53cf9c4c80007f58.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MKl5jRZDRsjI0wty.3cCZQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/2714949d049301fe53cf9c4c80007f58.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/merck-kgaa-touts-next-wave-of-growth-at-jpm-healthcare-reaffirms-2025-guidance-eyes-2026-upside-2026-01-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-kgaa-touts-next-wave-154854027.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MKGAF"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T13:43:00+00:00",
    "headline": "Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings?",
    "summary": "ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica demand.",
    "url": "https://finance.yahoo.com/news/abbvies-oncology-segment-support-top-134300252.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "848f241a-2203-3ea1-a026-4030de3e187b",
      "content": {
        "id": "848f241a-2203-3ea1-a026-4030de3e187b",
        "contentType": "STORY",
        "title": "Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings?",
        "description": "",
        "summary": "ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica demand.",
        "pubDate": "2026-01-13T13:43:00Z",
        "displayTime": "2026-01-13T13:43:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NXvq4ox9.Dlnga3rarSarw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ut1qVl6so81FolVpx3AkvA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvies-oncology-segment-support-top-134300252.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvies-oncology-segment-support-top-134300252.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T17:34:52+00:00",
    "headline": "Merck Lifts Long-Term Revenue Target",
    "summary": "New drugs seen driving $70 billion by 2035",
    "url": "https://finance.yahoo.com/news/merck-lifts-long-term-revenue-173452104.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "415352e9-0986-38f5-a9af-f8c84a72f97b",
      "content": {
        "id": "415352e9-0986-38f5-a9af-f8c84a72f97b",
        "contentType": "STORY",
        "title": "Merck Lifts Long-Term Revenue Target",
        "description": "",
        "summary": "New drugs seen driving $70 billion by 2035",
        "pubDate": "2026-01-13T17:34:52Z",
        "displayTime": "2026-01-13T17:34:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/fade00561dc235e3b2954df3ba1a92bf",
          "originalWidth": 360,
          "originalHeight": 360,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Mg6c.rtdJM8QJBzjgs1FNA--~B/aD0zNjA7dz0zNjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/fade00561dc235e3b2954df3ba1a92bf.cf.webp",
              "width": 360,
              "height": 360,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VDJTeEqfEizJpf.jvcTHbg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/fade00561dc235e3b2954df3ba1a92bf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-lifts-long-term-revenue-173452104.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-lifts-long-term-revenue-173452104.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T17:27:00+00:00",
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Merck & Co., Bristol-Myers Squibb, Pfizer, Johnson & Johnson and more in the latest Market Talks covering Health Care.",
    "url": "https://www.wsj.com/business/health-care-roundup-market-talk-ab91a0b0?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "d5f617d3-f057-3b8c-9ae7-8e2e48f7211e",
      "content": {
        "id": "d5f617d3-f057-3b8c-9ae7-8e2e48f7211e",
        "contentType": "STORY",
        "title": "Health Care Roundup: Market Talk",
        "description": "",
        "summary": "Find insight on Merck & Co., Bristol-Myers Squibb, Pfizer, Johnson & Johnson and more in the latest Market Talks covering Health Care.",
        "pubDate": "2026-01-13T17:27:00Z",
        "displayTime": "2026-01-13T17:27:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/d5f617d3-f057-3b8c-9ae7-8e2e48f7211e/health-care-roundup-market.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/bd45e130fb5d221ae0c46fc72b2041d5",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ARM0GrkFQuANPgLprIGrwA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/bd45e130fb5d221ae0c46fc72b2041d5.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AsLL0hd96VZM1Aq90rZ1Kg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/bd45e130fb5d221ae0c46fc72b2041d5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/business/health-care-roundup-market-talk-ab91a0b0?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T17:35:00+00:00",
    "headline": "ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon",
    "summary": "AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.",
    "url": "https://finance.yahoo.com/news/abbv-inks-drug-pricing-deal-173500494.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "9ba6192f-ca44-3a47-ba46-c14e9aaa3c18",
      "content": {
        "id": "9ba6192f-ca44-3a47-ba46-c14e9aaa3c18",
        "contentType": "STORY",
        "title": "ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon",
        "description": "",
        "summary": "AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.",
        "pubDate": "2026-01-13T17:35:00Z",
        "displayTime": "2026-01-13T17:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OQG3.5Wd9P9R69q2rhm9rA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pBlncPVBhEXpjxtBDlEOsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbv-inks-drug-pricing-deal-173500494.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbv-inks-drug-pricing-deal-173500494.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]